Earnings Releases·Nov 10, 2026, 8:15 AM ET

Atossa Therapeutics — Third Quarter 2026 Earnings Summary

Total operating expenses decreased 37% to $5.9 million in Q3 2026 and 5% to $24.5 million for the nine months ended September 30, 2026, driven by completed trial enrollments and reduced legal fees following patent litigation resolution; net loss narrowed to $5.6 million ($0.56/share) in Q3 and $23.7 million ($2.58/share) for the nine-month period.
Cash and cash equivalents declined to $20.6 million as of September 30, 2026, from $41.3 million at year-end 2025, while total stockholders' equity fell to $21.7 million from $39.4 million.
Management anticipates FDA IND clearance for (Z)-endoxifen in Duchenne Muscular Dystrophy and McCune-Albright Syndrome by early 2027, with Phase 2 trials expected to initiate in 2027, and top-line data from the Phase 2 EVANGELINE breast cancer study expected in Q2 2027.
On October 8, 2026, the Company entered into a Stapled Contingent Value Rights (CVR) Agreement granting holders 25% of net proceeds, up to $50 million, from the sale or monetization of the first qualifying FDA Priority Review Voucher.